Imricor Medical Systems Inc. (ASX: IMR) has been reinstated for trading on the Australian Securities Exchange (ASX) as of March 20, 2025. The company’s securities were previously suspended, and the trading halt has now been lifted following Imricor's official announcement concerning a capital raising initiative. This move indicates that the company has successfully secured new funding, which is often a strategic effort to support growth, operations, or research and development. The reinstatement is expected to restore investor confidence and market participation in the company’s shares. The ASX Compliance team issued the notice, highlighting that the resumption of trading came into effect immediately upon the capital raise disclosure. This marks a pivotal step for Imricor, positioning the company for its next phase of development in the medical technology space. Investors will now closely watch how the raised capital will be deployed to drive future value.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Mar 26, 2025
Mar 26, 2025
Mar 26, 2025
Mar 26, 2025
Mar 26, 2025
Mar 26, 2025
Mar 25, 2025
Mar 25, 2025
Mar 25, 2025
Mar 25, 2025
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
